News
10-23-2018, 12:20 AM
Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.
More... (https://www.news-medical.net/news/20181023/Study-reveals-new-treatment-option-for-women-with-advanced-breast-cancer-resistant-to-hormone-therapy.aspx)
More... (https://www.news-medical.net/news/20181023/Study-reveals-new-treatment-option-for-women-with-advanced-breast-cancer-resistant-to-hormone-therapy.aspx)